Patents Assigned to Teijin Pharma Limited
  • Publication number: 20240042226
    Abstract: Provided is a transcranial magnetic stimulator capable of providing a magnetic stimulation with a required intensity inside a brain even when a current value and a voltage value applied to magnetic stimulation coils in a plurality of resonant circuits are reduced. The transcranial magnetic stimulator includes a plurality of resonant circuits for applying respective pulse currents to a plurality of magnetic stimulation coils to generate variable magnetic fields, and a power source that supplies an electric power to the plurality of resonant circuits. The plurality of resonant circuits are connected in parallel to the power source, and therefore, the plurality of magnetic stimulation coils are also connected in parallel to the power source. The plurality of magnetic stimulation coils are formed in approximately a same shape, and adjacently disposed such that directions of magnetic fluxes generated by the applied pulse currents are matched.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 8, 2024
    Applicant: Teijin Pharma Limited
    Inventors: Hitoshi NAKAMURA, Kenji NANDOH
  • Publication number: 20240009477
    Abstract: An object of the present invention is to provide a phototherapy device with which a light irradiation region can be accurately positioned on a treatment site. The phototherapy device according to an embodiment of the present disclosure includes a barrel, a light source which is installed inside the barrel and which emits light, a plurality of imaging units for imaging a marking arranged on a body, a deviation amount calculation unit for calculating a deviation amount between a plurality of images of the marking included in a plurality of images captured by the plurality of imaging units, an image combining unit for combining the plurality of images of the marking based on the calculated deviation amount, a target position determination unit for determining a position of a target in the combined image corresponding to an irradiation region of light from the light source, and a display unit for overlaying and displaying an image of a target on the combined image of the marking.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 11, 2024
    Applicant: Teijin Pharma Limited
    Inventors: Takuya NANJO, Yuki KAWASE
  • Publication number: 20230285770
    Abstract: An object of the present invention is to provide a new indication for phototherapy or prevention, and to provide a new treatment or prevention device for irritable bowel syndrome. The present invention is a device for treating or preventing irritable bowel syndrome, specifically a light beam irradiation device for treating or preventing irritable bowel syndrome by performing percutaneous irradiation toward the sacral foramina on one side or both sides and the vicinity thereof.
    Type: Application
    Filed: July 20, 2021
    Publication date: September 14, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Naoya ISHIBASHI, Yuki KAWASE, Takuya NANJO
  • Patent number: 11739143
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 29, 2023
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME LLC
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Patent number: 11690971
    Abstract: Provided is an exacerbation prediction device equipped with a respiration sensing means of continuously sensing respiration data of a patient, a calculation means of calculating stable respiration data that are respiration data during a condition in which a respiratory rate is lowered and stable for a certain period of time from the sensed continuous respiration data of the patient, and a prediction means of predicting occurrence of an acute exacerbation in the patient in accordance with the stable respiration data calculated during a certain period of time.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: July 4, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Takayoshi Sato, Sadayoshi Matsumoto
  • Publication number: 20230192868
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Application
    Filed: March 2, 2023
    Publication date: June 22, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Hiroshi EGUCHI, Akira Tanokura, Kenichiro Takagi, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
  • Patent number: 11667707
    Abstract: The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: June 6, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Kenta Hibiya, Yusuke Kanamaru, Hirotsugu Kato
  • Patent number: 11666718
    Abstract: A respiratory information acquisition device used for a PSA type oxygen concentration device that switches and uses multiple adsorption cylinders includes a respiratory information acquisition means of measuring a first pressure of a periodic pressure fluctuation in an oxygen supply path when oxygen is supplied to a patient from the PSA type oxygen concentration device and a second pressure of a periodic pressure fluctuation in the oxygen supply path when oxygen is not supplied to the patient from the PSA type oxygen concentration device, a phase confirmation means of matching phases of the first pressure and the second pressure, and a subtraction processing means of calculating a difference between the first pressure and the second pressure in the condition where the phases are matched.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 6, 2023
    Assignee: Teijin Pharma Limited
    Inventor: Eisuke Kakinuma
  • Publication number: 20230167073
    Abstract: A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 1, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Sakae SUGIYAMA, Takuya YOKOSAKA, Kunio MINAMIZONO, Asahi KAWANA, Toshiyuki KANEKO, Akinobu MARUYAMA, Kosuke SASAKI, Shinnosuke HOSODA, Masaki KOSHIMIZU, Susumu TAKEUCHI, Kenta KATO, Nagasree CHAKKA, Brett M. JOHNSON, Ryan D. WHITE, Wei ZHAO
  • Publication number: 20230120349
    Abstract: Provided is an oxygen concentration device that can facilitate easy and secure replacement work, such as attaching and detaching the adsorption cylinder while reducing the force applied from the oxygen concentration device body to the adsorption cylinder cartridge in the direction of detaching and thus ensuring the connection with the oxygen concentration device, wherein the axis line of the gas flow direction of the adsorption cylinder intersects with either connection axis in the end part for supplying pressurized air to the adsorption cylinder or the end part for extracting oxygen from the adsorption cylinder.
    Type: Application
    Filed: March 25, 2021
    Publication date: April 20, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Yuichi HIRAI, Akinobu MURAMOTO
  • Patent number: 11629194
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: April 18, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Hiroshi Eguchi, Akira Tanokura, Kenichiro Takagi, Hirotsugu Kato, Satoshi Yamamura, Naoko Namiki
  • Patent number: 11571588
    Abstract: An object of the present invention is to provide a chair-type phototherapy device that enables a patient to perform light irradiation accurately targeted at a treatment site in a seated position on a chair and consequently achieves effective phototherapy even when the treatment site is in the back region that the patient is unable to see, for example, as in light irradiation for dysuria patients and patients with pain, and the patient performs light irradiation by himself/herself at home. The present invention provides a chair-type phototherapy device having a seat on which a patient is seated. The chair-type phototherapy device includes a radiation module configured to emit radiation light toward a living body, a drive module positioned behind the patient for moving the radiation module, and a fixing module fixing the drive module to the seat.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: February 7, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Naoya Ishibashi, Yuki Kawase, Takuya Nanjo, Takamitsu Okayama
  • Publication number: 20220340646
    Abstract: [Summary] [Purpose] The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders. [Solution Means] The invention provides an antibody that participates in antigen-antibody reaction specifically with tau protein that has been phosphorylated in the vicinity of Ser413 of SEQ ID NO: 1, and a therapeutic agent or prophylactic agent for cognitive disorders comprising as an active ingredient a peptide that has been phosphorylated in the vicinity of Ser413.
    Type: Application
    Filed: December 1, 2021
    Publication date: October 27, 2022
    Applicants: OSAKA CITY UNIVERSITY, TEIJIN PHARMA LIMITED
    Inventors: Hiroshi MORI, Takami TOMIYAMA, Yoichi MATSUMOTO, Hiroshi EGUCHI, Yuichi KUNORI
  • Patent number: 11458278
    Abstract: The device of the invention is equipped with a pressure sensor and a control unit, and the control unit judges a point at which a pressure gradient calculated from a signal of the pressure sensor becomes larger in the absolute value than a pressure gradient threshold as an inspiration sensing point and starts respiratory gas supply. In addition, the device judges from a frequency of the inspiration sensing point during predetermined time whether a pressure gradient threshold used as a criterion for the inspiration sensing point corresponds to an activity state of the user, and when the pressure gradient threshold does not correspond to the activity state, switches the pressure gradient threshold to another threshold and thus fits the pressure gradient threshold to the activity state.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 4, 2022
    Assignee: Teijin Pharma Limited
    Inventors: Masato Sasaki, Naoyuki Iida
  • Publication number: 20220296916
    Abstract: A phototherapy device 1 includes a laser light source 8 for emitting laser light at a target portion T, a limit switch 10 for detecting an approach of the laser light source 8 to a target portion T up to a predetermined distance and outputting a proximity signal, and an optical sensors 7 for detecting a distance to the target portion T and outputting a distance signal S corresponding to the distance and is configured so that a reference value L0 is set based on the distance signal S detected after the proximity signal is detected and emission of laser light by the laser light source 8 is permitted in accordance with an amount of fluctuation of the distance signal S with respect to the reference value L0.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 22, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Takuya NANJO, Yuki KAWASE, Toshihiro SATO, Kazunori TAKAHASHI
  • Publication number: 20220266053
    Abstract: A phototherapy device includes a laser light source 8 for emitting laser light toward a target portion, a body part 5, an intake port 12 provided at a side surface of the body part 5, a discharge port 13 provided at the side surface of the body part 5 at an opposite side from the intake port 12, and an air supply device 14 for supplying air to be ejected from the intake port 12 to the inside of the body part 5, the intake port 12 configured so that an ejection direction FO of the air is toward the near side from a center of an emission area A of the laser light at the target portion T.
    Type: Application
    Filed: December 22, 2020
    Publication date: August 25, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Takuya NANJO, Naoya ISHIBASHI
  • Patent number: 11386765
    Abstract: A server 20 for monitoring of the state of use of an oxygen concentrator 10 that concentrates oxygen in air and supplies it to a user, comprises a communication unit 25, and a processing unit 21 that uses the communication unit 25 to receive operation data indicating the state of operation of the oxygen concentrator 10 and usage data for the state of use by the user using the oxygen concentrator 10, measured by a measuring apparatus 11, 12, while also generating message information when either or both the usage data and operation data fail to satisfy the monitoring conditions, and sending the message information together with the usage data and operation data, using the communication unit 25.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: July 12, 2022
    Assignee: Teijin Pharma Limited
    Inventor: Taishi Ueda
  • Publication number: 20220204477
    Abstract: The present invention provides compounds which inhibit the activity of TRPC6, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 30, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Nagasree CHAKKA, Hua GAO, Angel GUZMAN-PEREZ, Brett Michael JOHNSON, Madeleine KIEFFER, Justin MALINOWSKI, Laurie SCHENKEL
  • Patent number: 11338101
    Abstract: An oxygen supply device supplying a user with an oxygen gas for inhalation acquires information of the user on percutaneous arterial oxygen saturation (SpO2) using a sensor unit, and calculates, from SpO2, the first moving average value and the second moving average value calculated over a time span longer than the first moving average in a control unit. The control unit calculates a Dip frequency during predetermined time from the SpO2 information, and when the calculated frequency is equal to or larger than the first threshold, the control unit switches the control from the control based on the first moving average value of SpO2 to the control based on the second moving average value.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: May 24, 2022
    Assignee: Teijin Pharma Limited
    Inventors: Ryo Koizumi, Sadayoshi Matsumoto
  • Patent number: 11332459
    Abstract: The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 17, 2022
    Assignee: TEIJIN PHARMA LIMITED
    Inventors: Michael D. Bartberger, Nagasree Chakka, Hua Gao, Angel Guzman-Perez, Daniel B. Horne, Zihao Hua, Madeleine Kieffer, Daniel C. H. Lin, Benjamin Charles Milgram, Jane Panteleev, Laurie Schenkel, John Stellwagen, Matthew Weiss, Ryan D. White, Wei Zhao